Servier and Ideaya Biosciences entered an exclusive license agreement on September 2, 2025.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Servier and Ideaya Biosciences entered an exclusive license agreement on September 2, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Servier has been named as a global partner in the OptimUM-11 clinical trial.Sub-event
Servier and Ideaya Biosciences entered an exclusive license agreement.1 source
Keep exploring
The entities involved
-
Ideaya Biosciences (United States)
company in South San Francisco, United States
Nothing else this week.
-
Servier
company in Madrid, Spain
Nothing else this week.
Coverage
Newest first; wire copies grouped- PR NewswireServier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide Servier and IDEAYA Biosciences enter into an exclusive license agreement for